Medicines in a popular new class of weight loss drugs including Ozempic and WeGovy may put patients at a higher risk for severe digestive problems, such as stomach paralysis, pancreatitis and bowel obstructions, according to a new study in JAMA Medical Journal
The pharmacology is described in the peer-reviewed literature, and clinical effect sizes vary with indication, individual factors, and adherence
Throughout your journey, our team is here to provide personalized guidance and help you set realistic expectations for your weight loss timeline
J Xenobiotics 14(3):11091129 Hong R, Xu B (2022) Breast cancer: an up-to-date review and future perspectives
doi: 10.1016/j.lfs.2022.120590 188 InandikliogluNDoganyigitZOkanAKaymakESiliciS
For example, semaglutide 2.4mg (Wegovy) has demonstrated approximately 15% weight loss in clinical trials for obesity, while liraglutide 3mg (Saxenda) typically achieves 5-10% weight loss